Gavi and AVMA: one ecosystem, solving the world’s immunisation challenges
2.1 Accelerating impact – Protecting our world, protecting people, protecting communities
- Gavi is one of the most successful development initiatives in history, protecting people and communities around the world.
- Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1 billion children – and prevented more than 17.3 million future deaths, helping to halve child mortality in 78 lower-income countries. Building on this success, Gavi will accelerate its impact in the years to come, leveraging the latest innovations in vaccines and vaccine delivery to protect the next billion children in half the time as the first, and against more diseases, than ever before.
- Proof point: By 2030, Gavi’s portfolio of vaccines will provide protection against more diseases than ever.
- Proof point: Gavi’s introduction and scale-up of vaccines for deadly diseases such as malaria and HPV vastly increase its potential for saving lives, protecting health systems and unlocking economic potential.
- Proof point: AVMA has been designed to ensure supplies of vaccines for countries that need them the most, and to boost supply of vaccines against which there are currently critical shortages, such as cholera, yellow fever, Ebola and meningitis.
2.2 A vital part of our world’s health security system – Protecting the world
- Gavi has not only protected a whole generation of children from preventable diseases, it has helped to protect our entire world by preventing and responding to outbreaks of diseases that can so easily spread across borders.
- Proof point: Through routine immunisation, Gavi helps to prevent outbreak-prone diseases such as measles.
- Proof point: Thanks to Gavi's market shaping efforts, production of cholera vaccines has increased 18-fold in the last decade. Today, despite a massive surge in outbreaks in 2024, the Gavi-funded stockpile is fully replenished.
- Proof point: By maintaining stockpiles for other outbreak-prone diseases such as Ebola, yellow fever and meningitis, Gavi is fighting on the front line to help keep deadly diseases at bay.
- Proof point: As a co-lead of COVAX, Gavi helped deliver 2 billion COVID-19 vaccine doses to 146 countries during the pandemic.
- Proof point: Gavi is helping the world prepare for future pandemics by creating the US$ 2.5 billion Day Zero Financing Facility, making available up to US$ 1 billion for AVMA and applying its dose sharing expertise to outbreaks of other diseases such as mpox.
- Proof point: Facilities supported by AVMA will be able to be repurposed to produce vaccines in the event of a pandemic.
2.3 Sustainability is at the heart of Gavi’s model
- The Vaccine Alliance places the countries it partners with in the driving seat.
- Proof point: Interventions are designed specifically to enable countries to take on more and more ownership of their immunisation programmes as they grow and develop.
- Proof point: Over the next five years, countries will make their largest ever investment in immunisation, paying over 40% of the costs of their routine vaccines.
- Proof point: Since Gavi was established, 19 countries have transitioned from Gavi’s support as their per capita gross national income (GNI) levels have grown. One third of the original 73 Gavi-supported countries will have transitioned by 2030.
- Proof point: As the latest innovative financing mechanism to be designed by Gavi, AVMA will play a formative role in helping build a high-quality, sustainable manufacturing sector capable of supporting the African Union’s Platform for Harmonized African Health Products Manufacturing (PHAHM) ambition to manufacture at least 60% of the total vaccine doses required on the continent by 2040.
2.4 Driving health and growing economies
- Supporting Gavi is not just good for human health, it is also good for economic development, helping countries and families boost their income and enabling people’s livelihoods to flourish and prosper.
- Proof point: Every euro/dollar invested in Gavi generates 54 dollars/euros in wider economic benefits, making it among the best investments in development.
- Proof point: By investing up to US$ 1 billion in AVMA, Gavi is helping create a sustainable and high-value manufacturing sector for the African region, stimulating further investment across the entire vaccine value chain.
- Proof point: Between 2021 and 2025 alone, Gavi’s work will have generated over US$ 80 billion of economic benefits for Gavi-supported countries.
2.5 A partner at the heart of global health
- As a public-private partnership, Gavi’s unique model was always designed to unlock the comparative advantages of its broad array of stakeholders. In this same spirit of partnership, Gavi today works alongside new partners in ways that strengthen health systems, create efficiencies and open up entry points for other vital programmes, such as nutrition to reduce food insecurity.
- Proof point: Empowering local actors and a gender-focused approach to immunisation will target hard-to-reach communities. Between 2026 and 2030, Gavi will facilitate hundreds of millions of contacts between families and health services through routine vaccination.
- Proof point: Gavi and the Global Fund work together closely to enhance malaria prevention in sub-Saharan Africa, by ensuring access to all tools and interventions.
2.6 An integral part of climate adaptation and AMR prevention
- As the climate crisis and rising antimicrobial resistance (AMR) continue to place great strain on the health systems of lower-income countries, vaccination is one of the strongest and most effective interventions. Half of Gavi’s vaccine portfolio will help countries adapt and respond to these twin threats.
- Proof point: Cholera, Japanese encephalitis, malaria, meningitis, typhoid and yellow fever are some of the climate-sensitive diseases in Gavi’s portfolio.
- Proof point: Gavi’s efforts over the next strategic period can help turn the tide against AMR: Hib, pneumococcal, rotavirus and typhoid vaccination in Gavi-eligible countries could significantly reduce the use of antibiotics.
- Proof point: Gavi works with countries to adapt routine immunisation programmes so they can be sustained through outbreaks and other health emergencies.
2.7 Empowering women and supporting gender equality
- Tackling gender inequality means improving social, health and economic outcomes. In its next strategic period, Gavi will continue to sharpen its focus on gender to overcome barriers to access and help empower the predominantly female health care workforce.
- Proof point: Millions of young women and girls will be protected from HPV between 2026 and 2030.
- Proof point: Gavi is helping make health services more accessible and safer for women and girls; supporting the recruitment and training of women health workers and addressing their specific needs in the workplace; and providing services at times and places convenient for mothers, while also engaging fathers.
- Proof point: Working directly with fathers in Togo has helped to reach more than 80% of children previously missing vaccination in targeted communities, while working with local and religious leaders in Papua New Guinea has improved the safety of women health workers.
2.8 Innovation, and value for money, is in Gavi’s DNA
- AVMA is the latest example of how Gavi uses financial innovation to address vaccine supply constraints and unlock new sources of funding for immunisation.
- Proof point: In helping to set up the International Finance Facility for Immunisation (IFFIm), Gavi has unlocked US$ 8.7 billion of funding through vaccine bonds.
- Proof point: Through its Advance Market Commitments (AMCs) for pneumococcal and COVID-19 vaccines, Gavi incentivised vaccine production suitable for low-income countries that otherwise would have been left out of the marketplace.
